Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2020 from OUS - Department of Molecular Oncology (2006-2014 Dept of Cancer Prev.)

11 publications found

Bergsland CH, Bruun J, Guren MG, Svindland A, Bjørnslett M, Smeby J, Hektoen M, Kolberg M, Domingo E, Pellinen T, Tomlinson I, Kerr D, Church DN, Nesbakken A, Sveen A, Lothe RA (2020)
Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer
ESMO Open, 5 (6), e001040
DOI 10.1136/esmoopen-2020-001040, PubMed 33219056

Bruun J, Kryeziu K, Eide PW, Moosavi SH, Eilertsen IA, Langerud J, Røsok B, Totland MZ, Brunsell TH, Pellinen T, Saarela J, Bergsland CH, Palmer HG, Brudvik KW, Guren T, Dienstmann R, Guren MG, Nesbakken A, Bjørnbeth BA, Sveen A, Lothe RA (2020)
Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
Clin Cancer Res, 26 (15), 4107-4119
DOI 10.1158/1078-0432.CCR-19-3637, PubMed 32299813

Flatin BTB, Vedeld HM, Pinto R, Langerud J, Lind GE, Lothe RA, Sveen A, Jeanmougin M (2020)
Multiregional assessment of CIMP in primary colorectal cancers: Phenotype concordance but marker variability
Int J Cancer, 148 (7), 1652-1657
DOI 10.1002/ijc.33425, PubMed 33284993

Guldvik IJ, Zuber V, Braadland PR, Grytli HH, Ramberg H, Lilleby W, Thiede B, Zucknick M, Saatcioglu F, Gislefoss R, Kvåle R, George A, Grönberg H, Wiklund F, Neal DE, Gnanapragasam VJ, Taskén KA, Mills IG (2020)
Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification
Eur Urol Open Sci, 21, 51-60
DOI 10.1016/j.euros.2020.08.007, PubMed 34337468

Hoff AM, Kraggerud SM, Alagaratnam S, Berg KCG, Johannessen B, Høland M, Nilsen G, Lingjærde OC, Andrews PW, Lothe RA, Skotheim RI (2020)
Frequent copy number gains of SLC2A3 and ETV1 in testicular embryonal carcinomas
Endocr Relat Cancer, 27 (9), 457-468
DOI 10.1530/ERC-20-0064, PubMed 32580154

Jeanmougin M, Håvik AB, Cekaite L, Brandal P, Sveen A, Meling TR, Ågesen TH, Scheie D, Heim S, Lothe RA, Lind GE (2020)
Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment
Mol Oncol, 14 (5), 1016-1027
DOI 10.1002/1878-0261.12668, PubMed 32171051

Lopes N, Bergsland C, Bruun J, Bjørnslett M, Vieira AF, Mesquita P, Pinto R, Gomes R, Cavadas B, Bennett E, Pereira L, Lothe RA, Almeida R, David L (2020)
A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis
Gastric Cancer, 23 (5), 811-823
DOI 10.1007/s10120-020-01064-6, PubMed 32215766

Smeby J, Kryeziu K, Berg KCG, Eilertsen IA, Eide PW, Johannessen B, Guren MG, Nesbakken A, Bruun J, Lothe RA, Sveen A (2020)
Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity
EBioMedicine, 59, 102923
DOI 10.1016/j.ebiom.2020.102923, PubMed 32799124

Vedeld HM, Folseraas T, Lind GE (2020)
Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis - The promise of DNA methylation and molecular biomarkers
JHEP Rep, 2 (5), 100143
DOI 10.1016/j.jhepr.2020.100143, PubMed 32939446

Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020)
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
Blood Adv, 4 (9), 1859-1866
DOI 10.1182/bloodadvances.2019001325, PubMed 32374878

Zhao S, Hoff AM, Skotheim RI (2020)
ScaR-a tool for sensitive detection of known fusion transcripts: establishing prevalence of fusions in testicular germ cell tumors
NAR Genom Bioinform, 2 (1), lqz025
DOI 10.1093/nargab/lqz025, PubMed 33575572

 
Page visits: 647267